Internal Medicine

Medicine & Life Sciences

1. Multiple Myeloma 100%
2. Neoplasms 82%
3. Therapeutics 67%
4. Survival 52%
5. Primary Myelofibrosis 51%
6. Liver Transplantation 38%
7. Transplants 38%
8. Pancreatic Neoplasms 32%
9. Cholecystokinin Receptors 30%
10. Colorectal Neoplasms 30%
11. Drug Therapy 28%
12. Endoscopy 28%
13. secretin receptor 27%
14. Safety 25%
15. Bone Marrow 25%
16. Guidelines 24%
17. Breast Neoplasms 24%
18. Coccidioidomycosis 23%
19. gemcitabine 22%
20. Lenalidomide 22%
21. Confidence Intervals 21%
22. Adenocarcinoma 21%
23. Clinical Trials 21%
24. Echocardiography 21%
25. Polycythemia Vera 21%
26. Mutation 20%
27. Atrial Fibrillation 20%
28. Mortality 20%
29. Colonoscopy 20%
30. Genes 20%
31. T-Lymphocytes 19%
32. Biopsy 19%
33. Cell Transplantation 19%
34. Population 19%
35. Quality of Life 19%
36. Cholecystokinin 19%
37. Ligands 19%
38. Transplantation 19%
39. Transplant Recipients 19%
40. Hemorrhage 18%
41. Recurrence 18%
42. Liver 18%
43. Kidney 18%
44. Progression-Free Survival 18%
45. Infections 17%
46. Peptides 17%
47. Eosinophils 17%
48. Tissue Donors 17%
49. Proteins 17%
50. Bortezomib 17%
51. Pharmaceutical Preparations 16%
52. Equipment and Supplies 16%
53. Obesity 16%
54. Barrett Esophagus 16%
55. Physicians 16%
56. Lung 16%
57. INCB018424 16%
58. Incidence 16%
59. Essential Thrombocythemia 16%
60. Irritable Bowel Syndrome 16%
61. Plasma Cells 15%
62. G-Protein-Coupled Receptors 15%
63. Hepacivirus 15%
64. Gastroesophageal Reflux 15%
65. Patient Reported Outcome Measures 15%
66. Secretin 15%
67. B-Cell Chronic Lymphocytic Leukemia 14%
68. Allogeneic Cells 14%
69. Dexamethasone 14%
70. Dendritic Cells 14%
71. Polyps 14%
72. Pancreatitis 14%
73. Systematic Reviews 14%
74. Placebos 14%
75. Prostatic Neoplasms 14%
76. Stem Cell Transplantation 13%
77. Heart 13%
78. Stem Cells 13%
79. Cholangiocarcinoma 13%
80. Renal Cell Carcinoma 13%
81. Randomized Controlled Trials 13%
82. Kidney Transplantation 13%
83. Pharmacokinetics 13%
84. Stomach 12%
85. Heart Failure 12%
86. Waldenstrom Macroglobulinemia 12%
87. Serum 12%
88. Technology 12%
89. B-Lymphocytes 12%
90. Esophageal Neoplasms 11%
91. Costs and Cost Analysis 11%
92. Biliary Tract Neoplasms 11%
93. Graft vs Host Disease 11%
94. Neoplasm Metastasis 11%
95. Fibrosis 11%
96. Asthma 11%
97. Irinotecan 11%
98. Elderly 11%
99. Meta-Analysis 11%